
-
Biofrontera NASDAQ:BFRI
Location: | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
6.715M
Cash
2.881M
Avg Qtr Burn
-4.53M
Short % of Float
4.33%
Insider Ownership
20.71%
Institutional Own.
36.47%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ameluz® - PDT (3 tubes) Details Actinic keratosis | Approved Quarterly sales | |
BF-RhodoLED® XL combo w/ Ameluz® Details Actinic keratosis | Approved Quarterly sales | |
XEPI (ozenoxacin) Details Impetigo | Approved Quarterly sales | |
Ameluz (aminolevulinic acid hydrochloride) Details BCC (basal cell carcinoma), AK (actinic keratosis) | Approved Quarterly sales | |
Ameluz® Details Actinic keratosis | sNDA Submission | |
Ameluz®-PDT combo w/ BF-RhodoLED® Details Superficial basal cell carcinoma | Phase 3 Update | |
BF-RhodoLED® XL combo w/ Ameluz® Details Actinic keratosis, Acne | Phase 2 Data readout |